Good
Mostly Aligned
Patient Risk:
Moderate
Summary
Most neuropsychiatric warning-related claims (including examples and counseling to discontinue/contact a provider) are aligned with the supplied label excerpts; however, the response includes multiple efficacy/dosing/administration and interaction/generic-form claims that cannot be verified against the provided label text (only Warning 5.1, Adverse Reactions 6.2, Indications 1.3, and Counseling 17 were supplied).
Category Scores
Accurate Statements
Mood or behavior changes can be serious with montelukast.
Label 5.1 Neuropsychiatric Events and 6.2 Postmarketing Experience describe serious neuropsychiatric events including behavioral changes.
Montelukast carries an important warning about neuropsychiatric events.
Label 5.1 Neuropsychiatric Events (Warnings and Precautions) and cross-reference to boxed warning content per excerpts.
Neuropsychiatric events with montelukast can include sleep problems.
Label 5.1 Neuropsychiatric Events lists insomnia/dream abnormalities.
Neuropsychiatric events with montelukast can include agitation.
Label 5.1 Neuropsychiatric Events and 6.2 Postmarketing Experience include agitation/aggressive behavior.
Neuropsychiatric events with montelukast can include depression.
Label 5.1 Neuropsychiatric Events and 6.2 Postmarketing Experience include depression.
Neuropsychiatric events with montelukast can include suicidal thoughts.
Label 5.1 Neuropsychiatric Events includes suicidal thoughts and behavior (including suicide).
Patients and caregivers are advised to seek medical advice right away if neuropsychiatric symptoms appear with montelukast.
Label 5.1 instructs to discontinue and contact a healthcare provider immediately if new/worsening neuropsychiatric symptoms or suicidal thoughts/behavior occur.
Neuropsychiatric symptoms can start or worsen after beginning montelukast.
Label 5.1 states NP events have been reported mostly during SINGULAIR treatment, and provides instructions regarding new/worsening symptoms.
Montelukast blocks leukotrienes.
Leukotrienes are signals involved in inflammation in the airways.
Unsupported Statements
Montelukast is used to help prevent or control asthma symptoms.
The supplied label excerpts only include Indications 1.3 Allergic Rhinitis and do not provide asthma indication text.
Montelukast is used to help prevent exercise-induced bronchoconstriction.
The supplied label excerpts do not include the exercise-induced bronchoconstriction indication.
Montelukast is used to help prevent or control allergic rhinitis (seasonal and/or year-round) in some patients.
Likely aligned with allergic rhinitis indication, but the excerpt in 1.3 specifies symptom relief and age thresholds (2 years+ seasonal; 6 months+ perennial). The claim does not include these specifics; verification is therefore incomplete with provided text.
Dosing of montelukast depends on the patient’s age.
No dosing section or age-based dosing details are provided in the supplied excerpts.
Dosing of montelukast depends on the condition being treated.
No dosing section details are provided in the supplied excerpts.
Dosing of montelukast depends on the prescribed formulation.
No dosing/formulation-specific instructions are provided in the supplied excerpts.
Tablets and chewable tablets are available for different age groups.
No formulation/age availability details are provided in the supplied excerpts.
Montelukast is typically taken once daily.
No dosing frequency guidance is provided in the supplied excerpts.
Commonly reported side effects of montelukast can include headache.
No common adverse reaction list is provided in the supplied excerpts (only postmarketing NP events are shown).
Commonly reported side effects of montelukast can include stomach or digestive upset.
No adverse reaction frequency list is provided in the supplied excerpts.
Commonly reported side effects of montelukast can include tiredness.
No adverse reaction frequency list is provided in the supplied excerpts.
Montelukast is not a substitute for rescue inhalers (like albuterol).
No rescue inhaler substitution warning text is included in the supplied excerpts.
Montelukast is not a substitute for inhaled corticosteroids when those are prescribed for asthma control.
No inhaled corticosteroid substitution language is included in the supplied excerpts.
Montelukast can be used as an add-on or alternative in specific situations.
No such treatment-role language is included in the supplied excerpts.
Montelukast can be used as a controller medicine.
No controller/reliever characterization is included in the supplied excerpts.
Montelukast is aimed at long-term symptom prevention rather than immediate relief during an asthma flare.
No such symptom-timing/flare-relief statement is included in the supplied excerpts.
Benefits of montelukast for asthma prevention and allergic rhinitis symptom control can begin after starting.
No onset-of-benefit timing language is included in the supplied excerpts.
The timing of benefits after starting montelukast can vary by person.
No onset variability language is included in the supplied excerpts.
Key interaction considerations depend on a patient’s other medications and medical history.
No interaction section text is included in the supplied excerpts.
It is important to review a patient’s full medication list with a pharmacist or clinician when considering montelukast interactions.
No interaction counseling text is included in the supplied excerpts.
Interaction review is especially important if a patient takes medicines that affect liver metabolism.
No interaction mechanism/“liver metabolism” language is included in the supplied excerpts.
Interaction review is especially important if a patient has other chronic conditions.
No interaction guidance based on chronic conditions is included in the supplied excerpts.
Montelukast is available as generic medication in many markets.
No statements about generic availability are included in the supplied excerpts.
Singulair is a brand name for montelukast.
No brand/generic mapping statement is included in the supplied excerpts.
Montelukast blocks leukotrienes.
No mechanism statement is included in the supplied excerpts.
Leukotrienes are signals involved in inflammation in the airways.
No mechanistic description is included in the supplied excerpts.
Contradictions
Important Omissions
For neuropsychiatric events, the label excerpt specifies that the benefits may not outweigh risks in some patients, particularly when disease symptoms are mild/adequately treated with alternatives, and includes specific guidance about reserving use (especially for allergic rhinitis).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Neuropsychiatric warning-related counseling largely matches the supplied label text, but multiple other claims (dosing, common adverse reactions, rescue/inhaled corticosteroid substitution, and interactions) are unverified against the provided label excerpts; inaccurate or incomplete dosing/administration guidance could affect safety if relied upon.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Aligned
Primary Issue
Many statements are not verifiable against the supplied FDA label excerpts because only neuropsychiatric warning/counseling and allergic rhinitis indication text were provided; several efficacy/dosing/side-effect/interaction assertions therefore lack label support in the materials provided.
Suggested Improvement
Limit claims to sections actually supplied (5.1 Neuropsychiatric Events, 6.2 Postmarketing Experience, 1.3 Allergic Rhinitis, and 17 Counseling), or provide the corresponding label sections for dosing, indications beyond allergic rhinitis, adverse reactions, rescue/inhaled corticosteroid warnings, and drug interactions before asserting those details.